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Background: Dendritic cells (DCs) are professional antigen-presenting cells that play a crucial role in the initiation
and modulation of immune responses. Human circulating blood DCs are divided into two major subsets: myeloid
DCs (mDCs); and plasmacytoid DCs (pDCs). Furthermore, mDCs are subdivided into two subsets: Th1-promoting
mDCs (mDC1s); and Th2-promoting mDCs (mDC2s). Although CD1a, CD1c, and CD141 are generally used for
classifying mDC subsets, their adequacy as a specific marker remains unclear. We performed this study to compare
circulating mDC, pDC, mDC1, and mDC2 subsets between Th1- and Th2-mediated diseases using CD1a and CD141,
and to analyze the adequacy of CD1a and CD141 as a marker for mDC1s and mDC2s, respectively.
Methods: Thirty patients with sarcoidosis, 23 patients with atopic diseases, such as atopic bronchial asthma, and 23
healthy subjects as controls were enrolled in this study. Peripheral blood DC subsets were analyzed with flow
cytometry according to expressions of CD11c, CD123, CD1a, and CD141. For functional analysis, we measured
interleukin (IL) 12p40 levels produced by the sorted mDC subsets.
Results: The sarcoidosis group showed decreased total DC (P < 0.05) and mDC counts (P < 0.05) compared to controls.
The atopy group showed decreased CD1a+mDC count (P < 0.05), and increased CD1a-mDC count (P < 0.05) compared
to controls. CD141+mDC count in the atopy group was higher than controls (P < 0.05). Sorted CD1a+mDCs produced
higher levels of IL-12p40 than CD1a-mDCs (P = 0.025) and CD141+mDCs (P = 0.018).
Conclusions: We conclude that decreased count of CD1a+mDC and increased count of CD141+mDC may reflect the
Th2-skewed immunity in atopic diseases. The results of IL-12 levels produced by the sorted mDC subsets suggested
the adequacy of CD1a and CD141 as a marker for mDC1 and mDC2, respectively, in vivo.
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Dendritic cells (DCs) are professional antigen (Ag)-
presenting cells (APCs) that originate from bone marrow
and play crucial roles in the initiation and modulation of
appropriate immune responses by linking innate to
adaptive immune response [1,2]. Immature DCs are
recruited from the blood circulation to peripheral or-
gans, where they continuously sample the environment
for foreign substances. These cells are able to take up
and process antigens, and immature DCs develop into* Correspondence: ishiiysk@dokkyomed.ac.jp
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reproduction in any medium, provided the ormatured DC during this process with the upregulated
expressions of major histocompatibility complex (MHC)
and costimulatory molecules in inflammatory microenvi-
ronments [3]. Subsequently, mature DCs migrate into
secondary lymphoid organs and present the processed
antigens to naïve T cells for the generation of effector
T cells and initiation of adaptive immune responses.
Human blood DCs comprise ~1% of peripheral blood
mononuclear cells and have been classically defined as
Ag-presenting leukocytes that lack other markers of
leukocyte lineages (CD3, 14, 16, 19, 20, and 56) and
express high levels of MHC class II (HLA-DR) mole-
cules [4]. CD11c+ myeloid DCs (mDCs) and CD123+l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subsets [5], with each playing distinct and complementary
roles in the induction of immune responses. Acting as
strong APCs, mDCs are efficient in the uptake, proces-
sing, and presentation of foreign antigens. Following Toll-
like receptor stimulation, mDCs produce tumor necrosis
factor α, and matured mDCs produce proinflammatory
cytokines such as interleukin (IL)-12. Conversely, pDCs
are less effective in these processes and mainly known for
their function in antiviral immunity and rapid production
of type I interferon.
DCs are also divided into functional subtypes as a
Th1-promoting subtype (DC1s) and a Th2-promoting
subtype (DC2s). In the past decade, mDCs and pDCs
have been thought to represent DC1s and DC2s, respec-
tively [6,7]. However, recent studies have led to a new
theory that both DC1s and DC2s differentiate from
mDCs, and in some reports, the terms mDC1 and mDC2
are used to describe the mDC subsets which promote
Th1 response and Th2 response, respectively. In fact,
mDC1s can be generated by cultivation of monocytes
with granulocyte macrophage colony-stimulating factor
(GM-CSF) and IL-4, whereas mDC2s can be generated
by cultivation of monocytes with IL-3 and IL-4 [8,9].
Although distinct markers of DC1 and DC2 have not
yet been fully established, CD1c (blood DC antigen
(BDCA)-1) and CD141 (BDCA-3) are generally used as
markers of mDC1 and mDC2, respectively [10-12]. In a
previous study, Th1-inducible DC subtype differentiated
from peripheral monocytes by cultivation with GM-CSF
expressed higher levels of CD1a than CD1c [9]. Based on
these data, we use CD1a as a better marker of mDC1s. In
contrast, the adequacy of CD141 as a marker for mDC2
remains controversial [13]. It is known that the expres-
sion of CD141 is not specific on mDCs, but also on pDCs
[14]. Detailed functional analysis of CD1a+mDCs and
CD141+ mDCs has yet to be fully discussed.
We therefore conducted a study to analyze peripheral
blood DC subsets, including mDC1 and mDC2, using
CD11c, CD123, CD1a and CD141, in patients with sar-
coidosis as a Th1-mediated disease and atopic diseases as
Th2-mediated diseases compared to healthy controls. In
addition, we measured and compared levels of IL-12p40
produced by sorted mDC subsets to confirm the adequacy
of CD1a and CD141 as a specific marker for circulating
blood mDC1 and mDC2 subsets, respectively.
Methods
Study subjects
Patients who were referred to our hospital for suspected
sarcoidosis or allergic bronchial asthma with or without
atopic dermatitis and allergic rhinitis from 2009 to 2011
were enrolled in this study. In all the patients with sar-
coidosis, the diagnosis was made from a biopsy obtainedeither from lung or lymph nodes and showing non-
caseating granulomas, and was made in accordance with
Japanese diagnostic criteria [15]. Patients who received
any steroid or immunosuppressive treatments were ex-
cluded. Clinical stage was classified according to Wurm’s
radiological staging [16,17]. Patients in the atopy group
were defined as having a history of non-treated allergic
bronchial asthma and/or atopic dermatitis and/or aller-
gic rhinitis, with positive radioallergosorbent test (RAST;
≥class 2) to house dust mite (HDM). Healthy volunteers
with negative RAST to HDM (class 0) were enrolled as
the control group. To exclude the influence of smoking
on peripheral DC populations, we chose only the sub-
jects who were never-smokers or ex-smokers that had
quitted smoking at least one year before the enrollment.
All the subjects provided informed consent prior to en-
rollment. The study was approved by the Institutional
Ethics Committee and was conducted in accordance
with the ethical principles embodied in the Declaration
of Helsinki.
Flow cytometric analysis
Twenty milliliters of heparinized blood was obtained for
DC isolation. Blood samples were stained with fluorescein
isothiocyanate-conjugated monoclonal antibody (mAb)
mixture for non-DC lineage leukocytes or lineage-negative
(lin-) cells with specificity for CD3, CD14, CD16, CD19,
CD20, and CD56, peridinin chlorophyll protein-conjugated
mAbs against HLA-DR, phycoerythrin-conjugated mAbs
against either the surface markers CD123 or CD1a,
allophycocyanin (APC)-conjugated CD11c (BD Biosci-
ences, San Jose, CA) or APC-conjugated CD141 (BDCA-3)
(Miltenyi Biotec, Bergisch Gladbach, Germany). Following
erythrocyte lysis and wash, stained leukocytes were ana-
lyzed by flow cytometry (FACS Calibur; BD Biosciences)
and acquired data were analyzed using CellQuest Software
(BD Biosciences). After gating mononuclear cells based on
side scatter and forward scatter (Figure 1A), the blood DC
population was identified as the lin-/ HLA-DR+ fraction
(Figure 1B). DCs were divided into a CD11c+DC subset
(mDCs) and a CD123+DC subset (pDCs) (Figure 1C). The
mDC subset was further subdivided into two subsets
based on the expression of CD1a (Figure 1D) and CD141
(Figure 1E). The number of total events was 200,000, and
data are expressed as DC counts per 200,000 leukocytes.
IL-12 production by sorted mDC subsets
One hundred milliliters of heparinized peripheral blood
was drawn from five healthy volunteers and stained with
the panel of mAbs described previously (See ‘ Flow
cytometric analysis’). Peripheral blood DCs are sorted as
lin-/HLA-DR+/CD11c+/CD1a+, lin-/HLA-DR+/ CD11c+/
CD1a-, lin-/HLA-DR+/CD123-/CD141-, and lin-/ HLA-












Figure 1 Flow cytometric analysis of dendritic cell (DC) population from whole blood. After gating mononucleolar cells based on side
scatter (SSC) and forward scatter (FSC) (A), blood DC population was identified as the lineage-/ HLA-DR+ fraction (B). DCs were divided into a
CD11c+ DC subset (mDC) and a CD123+ DC subset (pDC) (C). mDCs (CD11c+DCs or CD123-DCs) were divided into the further subgroups based
on the expression of CD1a (D) and CD141 (E). The results presented (D) and (E) are representative of the each group.
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(661.8, 1097.0) (460.0, 941.0) (922.6, 1279.0)
CD11c+DC (mDC)
481.0 320.0* 457.0
(352.0, 700.0) (226.0, 509.0) (284.0, 628.3)
CD123+DC (pDC)
90.0 110.5 127.0
(62.8, 143.5) (62.5, 168.5) (68.0, 268.0)
CD1a+mDC
351.0 238.5 215.0*
(217.0, 462.0) (139.8, 362.8) (118.0, 279.0)
CD1a-mDC
92.5 79.0 205.0*
(53.5, 144.5) (44.5, 135.0) (93.0, 324.5)
CD141-mDC
223.0 179.0 232.0
(167.0, 355.5) (126.0, 310.0) (142.0, 299.0)
CD141+mDC
90.5 116.5 261.0*
(52.3, 265.3) (66.5, 166.3) (81.5, 361.3)
Data were expressed as the DC counts per 200,000 leukocytes. Data are
presented as median with interquartile range. *P < 0.05 vs control.
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tissue culture plate at 1 × 104 cells/well in medium
supplemented with RPMI 1640, 10% fetal bovine
serum, penicillin 100 μg/ mL, and lipopolysaccharide
100 ng/mL. After cultivation for 48 h, IL-12p40 levels
in each supernatant were measured with purchased
enzyme-linked immunosorbent assay kits (R&D Sys-
tems, Minneapolis, MN).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5.04 (Graphpad Software, San Diego, CA). Data
are summarized as mean with standard deviation (SD)
or median with interquartile range (IQR) depending on
distribution. Statistical differences in DC counts or ratios
between groups were assessed using Kruskal-Wallis test,
and subsequent post hoc analyses were performed using
Dunn’s test. The paired t-test was used to compare mean
values between groups. Differences were considered sig-
nificant for values of P < 0.05.
Results
Patient characteristics
Thirty patients with sarcoidosis (13 men, 17 women;
mean age, 48.3 ± 15.3 years), 23 patients with atopic dis-
eases (16 men, 7 women; mean age 45.5 ± 14.8 years),
and 23 healthy controls (10 men, 13 women; 51.7 ± 14.0 -
years) were enrolled in the study (Table 1).
CD11c+DC (mDC) and CD123+DC (pDC) subsets
All the data for the DC subset are shown in Table 2. In
the sarcoidosis group, both total DC [median (IQR):
632.5 (460.0, 941.0)] and mDC [320.0 (226.0, 509.0)]Table 1 Characteristics of patients and control group
Sarcoidosis Atopy Control
(n = 30) (n = 23) (n = 23)
Age: mean ± SD (range) 48.3 ± 15.3 45.5 ± 14.8 51.7 ± 14.0
(25–72) (26–70) (27–67)
Sex 13/ 17 16/ 7 10/ 13
(male/female)
stage I 8 (26.7%) - -
II 20 (66.7%)
III 2 (6.7%)
BA alone - 7 -
AD alone 2
AR alone 8
BA + AD 2
BA + AR 3
AD + AR 1
BA + AD + AR 0
BA; bronchial asthma, AD; atopic dermatitis, AR; allergic rhinitis.counts were significantly decreased than controls [total
DC: 908.0 (661.8, 1097.0) (P < 0.05), mDC: 481.0 (352.0,
700.0) (P < 0.05)] (Figure 2). pDC count was not differ-
ent among the three groups. mDC count was superior to
pDC count in all the three groups, and mDC/pDC-ratio
did not differ among the groups (data not shown).CD1a+mDC and CD1a-mDC subsets
CD1a+mDC count was equivalent in the sarcoidosis
group: 238.5 (139.8, 362.8) and healthy controls: 351.0
(217.0, 462.0), but was significantly decreased in the atopy
group: 215.0 (118.0, 279.0) (P < 0.05, Figure 3). CD1a-
mDC count in the atopy group: 205.0 (93.0, 324.5) wascontrol sarcoidosis atopy










Figure 2 Comparison of myeloid DC (mDC) and plasmacytoid
DC (pDC) subsets. CD11c+DC (mDC) subset was decreased in the
sarcoidosis group (P < 0.05). CD123+DC (pDC) count was not
different among the three groups. Data were expressed as the DC









control   sarcoidosis   atopy control   sarcoidosis   atopy 
* *
*
Figure 3 Comparison of CD1a+mDC and CD1a- mDC subset.
CD1a+mDC subset was decreased in the atopy group compared to
controls (P < 0.05) . CD1a-mDC subset was increased in the atopy
group compared to both controls (P < 0.05) and the sarcoidosis













  CD1a+mDC  CD1a-mDC      CD141-mDC  CD141+mDC 
* P=0.025
Figure 5 Comparison of IL-12p40 levels produced by sorted
mDC subsets. Sorted CD1a+mDC produced significantly higher
level of IL-12p40 compared to both CD1a-mDC (P = 0.025) and
CD141+mDC (P = 0.018). There was no difference in production of IL-
12p40 between CD141-mDC and CD141+mDC.
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and the sarcoidosis group: 79.0 (44.5, 135.0) (P < 0.05).
CD141-mDC and CD141+mDC subsets
No differences were seen in CD141-mDC count among
the three groups (Figure 4). In contrast, CD141+mDC
count was significantly increased in the atopy group
compared to controls [atopy: 261.0 (81.5, 361.3), control:
90.5 (52.3, 265.3)] (P < 0.05).
IL-12p40 levels produced by sorted mDC subsets
Sorted CD1a+mDCs produced significantly higher
levels of IL-12p40 (17.3 ± 3.1 pg/mL) when compared
with CD1a-mDCs (7.8 ± 1.9 pg/mL, P = 0.025) and
CD141+mDCs (6.9 ± 0.8 pg/mL, P = 0.018, Figure 5).
CD141-mDCs showed a trend toward producing
higher levels of IL-12p40 (9.3 ± 0.8 pg/mL) whenCD141-mDC CD141+mDC 









Figure 4 Comparison of CD141-mDC and CD141+mDC subset.
CD141-mDC subset was not different among the three groups. In
contrast, CD141+mDC in the atopy group was significantly increased
than controls (P < 0.05). Data were expressed as the DC counts per
200,000 leukocytes.compared with CD141+mDCs (6.9 ± 0.8 pg/mL Figure 5,
Table 3), but the difference was not significant (P = 0.435).
Discussion
In this study, we have reported differences of peripheral
blood DC subsets between sarcoidosis and atopic dis-
eases using four-color flow cytometry, and have analyzed
the adequacy of CD1a and CD141 as a marker for
mDC1 and mDC2, respectively by the production of IL-
12p40. Sarcoidosis patients showed decreased peripheral
total and myeloid DC count with similar population of
both CD1a+ mDC and CD141+mDC subsets compared
to the control subjects. In contrast, patients with atopic
diseases showed lower CD1a+mDC count and higher
CD141+mDC count, which suggests the involvement of
CD1a-mDCs and CD141+mDCs in Th2-polarity in
atopic diseases.
In recent years, many studies have examined quantita-
tive alternations of circulating blood DCs in patients
with different pathological conditions, for example, Th1-
mediated diseases such as viral infections and cancers,
or Th2-mediated diseases such as bronchial asthma and
atopic dermatitis [18-20]. Most investigations have fo-
cused on the proportion of mDC and pDC subsets. After
a report describing two further subsets in mDCs,
mDC1s as a Th1-promoting mDC subtype and mDC2s
as a Th2-promoting mDC subtype [21], an increasing
number of studies have been analyzing mDC1/mDC2
subsets using CD1c or CD1a, and CD141 [10,11] has
been reported. CD1a and CD1c are the subgroup of
CD1, which is structurally and functionally similar to
MHC class I and II molecules; however, CD1 presents
lipids and glycolipids rather than polypeptides on DCs.
CD1 has also evolved a unique path of intracellular
trafficking, processing, and loading of lipid antigens.
CD141, thrombomodulin, is a glycoprotein on the
Table 3 Comparison of IL-12p40 levels produced by sorted mDC subsets
CD1a+mDC CD1a-mDC CD141-mDC CD141+mDC
IL-12p40 (pg/mL) (range) 17.3 ± 3.1 7.8 ± 1.9 9.3 ± 0.8 6.9 ± 0.8
(10.1 – 27.2) (5.9 – 10.8) (7.3 – 11.8) (4.0 – 8.5)
Data are shown as mean ± SD.
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cofactor of thrombin in the anticoagulant pathway. The
immunological function of CD141 on mDCs is un-
known. Relatively few studies have analyzed human per-
ipheral blood mDC1 and mDC2 subsets. According to
previous studies [10,12] performed ex vivo, CD1a+mDCs
or CD1c+mDCs are generally accepted as representing
mDC1s and CD141+mDCs as representing mDC2s. Hata
et al. [9] succeeded in making mDC1s and mDC2s from
freshly isolated circulating monocytes using either GM-
CSF with IL-4 or IL-3 with IL-4, respectively. Further-
more, they confirmed the potential of CD1a as a marker
for mDC1s through the differences in expression be-
tween mDC1 and mDC2 subsets. Based on these find-
ings and results of previous reports [10-12], we used
CD1a and CD141 in this study as a marker of mDC1s
and mDC2s, respectively.
Sarcoidosis is a multisystem disorder of unknown eti-
ology characterized by non-caseating granulomas that are
composed of epithelioid cells, fibroblasts, and several im-
mune cells such as T cells and histiocytes/macrophages.
Lungs, eyes and skin are the most affected organs. In sar-
coidosis, lung T cells are shown to spontaneously release
high levels of IL-2 and interferon γ [22-24], and studies of
T-cell clones from lung parenchyma [25] and of broncho-
alveolar lavage fluid (BALF) [26-29] support the opinion
of sarcoidosis as a Th1-mediated disease. Similarly, various
clinical studies, genetic studies and animal models of aller-
gic diseases support the notion that atopic diseases such
as bronchial asthma, atopic dermatitis and allergic rhinitis
are Th2-mediated disease.
In the present study, sarcoidosis patients showed
decreased total DC and mDC counts compared to
healthy controls. Previous studies have identified de-
creased numbers of total blood DCs and both subsets
of CD11c+-myeloid DCs and CD11c--lymphoid DCs [30].
Another report showed that sarcoidosis patients tended to
show decreased numbers of mDCs [31]. Our result was
similar to these previous reports. In sarcoidosis, circula-
ting blood DCs migrate into the affected tissues, contri-
buting to the formation of sarcoid granulomas. This
migration and accumulation into local inflammatory tis-
sues may decrease the number of DCs circulating in the
blood. Ota et al. showed the accumulation of DCs in the
lymphocyte layer of sarcoid granulomas [30].
We expected a predominance of CD1a+mDC count in
peripheral blood in patients with sarcoidosis. Contraryto our expectation, no such differences in numbers of
CD1a+mDCs and CD1a-mDCs were seen between sar-
coidosis and controls. In sarcoidosis, the immunity of
circulating blood does not always parallel that of locally
affected organs, as seen from granuloma or BALF in
lung tissue. For example, the CD4/CD8 ratio in BALF is
usually high in sarcoidosis, but is not increased in per-
ipheral blood. Given these findings, immunity of per-
ipheral blood in patients with sarcoidosis is thought
not to reflect the Th1/Th2 polarity. There are a few
reports demonstrating the expression of CD1a on
mDCs in the local inflammatory sites in sarcoidosis.
An investigation in the BALF of inflammatory dis-
eases showed an increase of CD1a-mDCs in sarcoi-
dosis [32]. Another study of immunohistochemical
investigation in muscular sarcoidosis demonstrated
that CD1c+ mDCs scattered mainly in the lymphocyte
layers of granulomas and the endomysium around the
granulomas, while CD1c+mDCs expressed the mature DC
marker CD83, but CD1a positive cells were not found by
double immunostaining [33]. Since expression of surface
markers on DCs is varied by the existing environment
such as in organ tissue or in blood circulation, and also by
the involved organs, precise evaluation is not easy. Further
investigation is necessary to define the local immunity in
sarcoidosis.
In the atopy group, numbers of total DC, mDC, pDC
were all equivalent to controls. A previous study
reported that total counts of circulating blood DCs were
increased in patients with asthma [34]. Some reports
have shown that allergen challenge causes a rapid de-
crease in the circulating mDC count [35] and an accu-
mulation of DCs in airway epithelium [36-38] in patients
with allergic asthma, while another report showed a
trend toward to decreased number of circulating blood
mDCs and a significant increase of pDCs in patients
with atopic asthma [18]. The different disease states of
the study participants may explain such contradictory
results. Contrary to previous reports, which performed
allergen challenge in patients with allergic asthma to in-
voke allergic inflammation, we examined stable atopic
patients with no medication in order to exclude any in-
fluence of medications. This might have contributed to
the unclear differentiation from controls. Actually,
Upham et al. reported that decreases in circulating
mDCs were most marked at 3 and 6 h post-allergen
challenge, gradually returning to baseline levels [35].
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significant decrease, while CD141+mDC count was sig-
nificantly increased compared to controls. Yerkovich et al.
reported that after allergen challenge the constitutive
expression of CD141 on mDCs was increased in atopic in-
dividuals compared to non-atopic subjects [12]. The same
group of investigators has also shown that CD141+mDCs
are associated with Th2 polarizing response, whereas
CD141-mDCs are associated with a mixed Th1/Th2 re-
sponse. On the other hands, Jongbloed et al. reported that
CD141+mDCs induce superior Th1 response compared to
CD1c+DCs [13], and the significance of CD141+mDCs is
still in dispute. The results of the present study may sup-
port the theory that CD1+mDCs and CD141+mDCs repre-
sent mDC1s and mDC2s, respectively. The decreased
mDC1s and increased mDC2s may reflect the Th2-
skewed immunity in atopic disease.
When discussing the adequacy of CD1a and CD141 as a
definite marker for mDC1s and mDC2s, respectively, the
ability of sorted CD1a+mDCs and CD141+mDCs to induce
Th1 and Th2, respectively, must be confirmed. However,
few reports have examined this area, because these proce-
dures need large amounts of peripheral blood, reducing
clinical feasibility. In a previous report, monocyte-derived
CD1a+mDCs produced high amounts of IL-12, a Th1-
inducible cytokine, and induced Th1 when co-cultured
with lymphocytes [10]. In our study, sorted CD1a+mDCs
produced significantly higher levels of IL-12p40 com-
pared to CD1a-mDCs. This result suggests that CD1a
can offer a marker for human peripheral blood mDC1s.
CD141+mDCs produced significantly less IL-12p40 com-
pared to CD1a+mDCs but no differences in produced
IL-12p40 levels were seen between CD141+mDCs and
CD141-mDCs. CD141-mDC subset is probably composed
of heterogeneous cell populations, and they are not always
represent mDC2 subset. So, our results imply the possibi-
lity of CD141 as a marker for mDC2, however, further in-
vestigation is necessary to clarify the meaning of the
expression of CD141 on mDCs as mDC2.
In the present study, we were unable to analyze CD1a/
CD141 double positive or double negative mDCs due to
technical limitations. There is almost no data about
them in human peripheral blood, however, Bratke et al.
showed that 45% of mDCs were CD1a positive and 78%
of mDCs were CD141 positive in the analysis of BALF
of never smokers [39]. It may be difficult to completely
identify mDC1 and mDC2 only using CD1a and CD141.
In future research, we feel it is necessary to find out the
number and function of CD1a/CD141 double positive
and double negative mDCs in human peripheral blood.
Conclusions
In conclusion, the present study shows, for the first time,
human circulating DC subsets including mDC1 andmDC2 comparing Th1-related to Th2-related disease.
These data suggests the involvements of mDC1s and
mDC2s in the Th1/Th2-polarity, and the adequacy of
CD1a as a marker for mDC1 and the possibility of
CD141 as a marker for mDC2.
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